Clinical Trials Logo

Filter by:
NCT ID: NCT02127684 Withdrawn - Clinical trials for Persistent Diabetic Macular Edema

Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing

Start date: n/a
Phase: Phase 2
Study type: Interventional

The investigators would like to investigate the efficacy of more frequent treatment with Lucentis for subjects with persistent diabetic macular edema despite standard dosing regimen.

NCT ID: NCT02127229 Withdrawn - Biliary Obstruction Clinical Trials

Cost Analysis for Endoscopic Retrograde Cholangiopancreatography (ERCP)

ERCP
Start date: April 2014
Phase: N/A
Study type: Interventional

The purpose of the study is to determine if endoscopist notification of accessory cost results in altered resource utilization related to the total cost and number of accessories used in ERCP. This study will be a prospective cost--analysis study. Only chart review of PHI removed records will be used. The only intervention used is that endoscopists will be made aware of the cost of accessories used in the second phase of the study following each ERCP. The investigators are in an era of increased medical cost consciousness. Medical education and post--graduate education incorporates cost savings and appropriate diagnostic test selection based on expense as one aspects of the decision process. This era now focuses on what is best for the patient with the understanding that the cost to the patient and cost to the overall health care system matters. Not only is this apart of postgraduate training but now being implemented as part of Medicare reimbursement to provide low cost and high quality care. Incidence of pancreatic and biliary disease is increasing. ERCP is a vital tool for therapeutic intervention. The costs of these procedures, to both patients and hospitals, have caused some to question the amount of accessories used as well as the poor reimbursement provided by Medicare and insurers. Studies have indicated that hospitals actually lose money with each ERCP used and their use is being limited many times to tertiary care centers.

NCT ID: NCT02126527 Withdrawn - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer

Start date: August 2013
Phase: Phase 1
Study type: Interventional

This phase I clinical trial studies the side effects and best dose of auranofin and sirolimus when given together in treating patients with non-small cell lung cancer. Immunosuppressive therapy, such as auranofin and sirolimus, may be an effective treatment for non-small cell lung cancer. Sirolimus may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving auranofin and sirolimus may be an effective treatment for non-small cell lung cancer.

NCT ID: NCT02126020 Withdrawn - Clinical trials for Stevens-Johnson Syndrome

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Start date: November 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The Boston Keratoprosthesis type I (KPro) is a prosthetic cornea used to treat several causes of corneal blindness. Some categories of patients, including those with auto-immune diseases such as Stevens-Johnson syndrome, toxic epidermal necrolysis syndrome and mucous membrane pemphigoid, have a higher risk of failure for the KPro. Because of chronic inflammation, the cornea supporting the KPro may melt, leading to a higher risk of infection, loss of the KPro and loss of the eye. Infliximab is an antibody against tumor necrosis factor alpha and is used intravenously to control inflammation in several diseases. It has been used in some cases of corneal melting with significant success. This study's hypothesis is that infliximab can be successfully used as an eye drop (instead of the usual administration through veins) and that its regular use may prevent melt in eyes with a Boston Keratoprosthesis type I and underlying auto-immune disease.

NCT ID: NCT02125591 Withdrawn - Clinical trials for Mild Traumatic Brain Injury

Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Full Trial)

CN-NINM
Start date: August 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate improvement in balance after receiving physical therapy when augmented by CN-NINM than when augmented by a placebo (sham CN-NINM).

NCT ID: NCT02124447 Withdrawn - Clinical trials for Patients Undergoing Screening or Surveillance Colonoscopy

Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy

Start date: June 2014
Phase: N/A
Study type: Interventional

This will be a 4-way comparison to prospectively evaluate the efficacy and patient tolerability of four commercially available bowel preparations among patients undergoing colonoscopy for screening and surveillance in a single tertiary academic medical center.

NCT ID: NCT02123498 Withdrawn - Clinical trials for Laryngopharyngeal Reflux

The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux

ETDLPR
Start date: n/a
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the relationship between ear fullness, pressure, and/or pain and laryngopharyngeal reflux, in order to focus medical therapy and improve therapeutic outcomes in this patient population.

NCT ID: NCT02123238 Withdrawn - Clinical trials for Obstructive Sleep Apnea

Positioning of Surgical Patients With Sleep Apnea

Start date: April 2014
Phase: N/A
Study type: Interventional

The study aims to evaluate the effect of non-supine positioning in the treatment of surgical patients with obstructive sleep apnea. The hypothesis is that non-supine positioning will result in a decrease in acute hypoxic events, defined as the number of apneas/hypopneas per hour of sleep.

NCT ID: NCT02123147 Withdrawn - Autoimmune Diseases Clinical Trials

Examining the Immunological Process of Autoimmune Patients

Start date: July 2014
Phase: N/A
Study type: Observational

Sjögren's syndrome (SjS) is an autoimmune disease characterized primarily by exocrine gland dysfunction, specifically of the salivary and lacrimal glands, resulting in dry mouth and dry eyes symptoms. It can be systemic by affecting other organs including the gastrointestinal tract, skin, lungs, vasculature, kidneys, bladder and vagina. Involvement of the musculature can lead to fibromyalgia-like symptoms and chronic fatigue, while approximately 20% of patients develop various neuropathies, including sensory, peripheral, cranial and myelopathic neuropathies exhibited by cognitive impairments such as dementia, lack of concentration, memory loss and various psychiatric disorders. Like most autoimmune connective tissue diseases, SjS shows a sexual dimorphism with women affected 10-times more frequently than men, suggesting a role for sex hormones in disease susceptibility or progression. One common feature of SjS is it infiltration of mononuclear cells into the salivary and lacrimal glands, aggregating into clusters referred to as lymphocytic foci (LF). Critical to the studies proposed is the fact that a predominant cell population of LF is the pathogenic TH17 cell that produces IL-17 cytokine and autoreactive B cells reactive to M3R, Ro, and La autoantigens. The goal of this study is characterize the change in receptor gene repertoires of autoreactive B and T cells at different time points during the disease process and examine the correlation with various disease parameters.

NCT ID: NCT02122835 Withdrawn - Heart Failure Clinical Trials

Exercise, Heart Failure, and Type 2 Diabetes

Start date: February 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to understand the differences in how patients with heart failure respond to exercise training compared to patients with heart failure and type 2 diabetes.